What is Moderna's 52-week high?

The 52-week high reached $185.40, up 12% from the previous session.

Did this announcement affect other mRNA stocks?

Yes, BioNTech and CureVac shares rose 3-5% on similar optimism.

Moderna Stock Hits 52-Week High on Expansion Plans Beyond Vaccines

Moderna (MRNA) stock jumped to a 52-week high after the company announced a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases, and AI-driven R&D.

June 29, 2026

2 min read

Source: Zacks

Moderna (MRNA) stock hit a 52-week high on Monday after the company unveiled a new strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases, and AI-driven research and development.

Reasons for the Move

The surge followed Moderna's announcement of plans to use mRNA technology to develop treatments for cancer and immune diseases, as well as integrating artificial intelligence into its R&D processes. Investors see this move as potentially opening new markets and diversifying the company's revenue streams.

Context

Moderna's stock had fallen about 40% year-to-date prior to this announcement, amid declining demand for COVID-19 vaccines. The rally marks a significant rebound, with the stock closing at $185.40, up 12% from the previous session.

Similar Moves in the Sector

The biotech sector overall saw positive moves this week, with stocks like BioNTech (BNTX) and CureVac (CVAC) rising between 3% and 5%, supported by similar optimism about future mRNA applications.

Frequently Asked Questions

Moderna stock rose after the company announced plans to expand its mRNA platform into oncology, autoimmune diseases, and AI-driven R&D.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.